A variation of the gene NFKB1, called rs4648127, is associated with an estimated 44 percent reduction in lung cancer risk. When this information, derived from samples obtained as part of a large NCI-sponsored prevention clinical trial, was compared with data on a different sample collection from NCI’s genome-wide association studies (GWAS), lung cancer risk was still estimated to be lower, but only by 21 percent. While this variation of gene NFKB1 had not previously been linked to lung cancer risk, a protein produced by the NFKB1 gene has been associated with several important roles in immunity, inflammation, and cell proliferation. Read more here.
Study mentioned: Shiels MS, et al. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer. 2012 Oct 8. [Epub ahead of print] PMID: 23044494
No comments:
Post a Comment